Your browser is no longer supported. Please, upgrade your browser.
iTeos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.25 Insider Own0.71% Shs Outstand35.05M Perf Week-10.74%
Market Cap808.54M Forward P/E- EPS next Y-2.71 Insider Trans-26.35% Shs Float34.80M Perf Month-43.67%
Income-43.40M PEG- EPS next Q-0.48 Inst Own77.30% Short Float3.79% Perf Quarter-38.79%
Sales- P/S- EPS this Y-55.40% Inst Trans8.13% Short Ratio4.40 Perf Half Y-0.62%
Book/sh9.22 P/B2.42 EPS next Y-19.50% ROA-17.50% Target Price- Perf Year-
Cash/sh9.27 P/C2.40 EPS next 5Y- ROE-30.30% 52W Range17.50 - 47.61 Perf YTD-34.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.20% Beta-
Dividend %- Quick Ratio22.60 Sales past 5Y- Gross Margin- 52W Low27.31% ATR2.84
Employees62 Current Ratio22.60 Sales Q/Q- Oper. Margin- RSI (14)31.34 Volatility8.57% 9.56%
OptionableNo Debt/Eq0.00 EPS Q/Q46.60% Profit Margin- Rel Volume0.58 Prev Close21.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume299.63K Price22.28
Recom1.50 SMA20-26.31% SMA50-37.12% SMA200-25.37% Volume173,439 Change5.99%
Oct-08-20Initiated Robert W. Baird Outperform $45
Aug-18-20Initiated Wedbush Outperform $45
Aug-18-20Initiated SVB Leerink Outperform $45
Aug-18-20Initiated Piper Sandler Overweight $50
Aug-18-20Initiated JP Morgan Overweight $40
Apr-10-21 08:30AM  
Mar-24-21 04:45PM  
Feb-23-21 07:00AM  
Feb-17-21 07:00AM  
Jan-25-21 02:13AM  
Jan-05-21 07:00AM  
Dec-11-20 02:00PM  
Nov-23-20 04:01PM  
Nov-12-20 07:01AM  
Nov-05-20 04:05PM  
Oct-26-20 08:27AM  
Oct-01-20 10:03AM  
Sep-08-20 04:05PM  
Sep-01-20 05:26PM  
Aug-07-20 08:15PM  
Jul-23-20 10:31PM  
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MPM BioVentures 2014, L.P.10% OwnerApr 09Sale29.991193,5693,665,787Apr 13 04:16 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 09Sale29.991193,5693,665,787Apr 13 04:15 PM
GADICKE ANSBERT10% OwnerApr 09Sale29.992005,9986,004,368Apr 13 04:15 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 08Sale30.5219,304589,0893,655,906Apr 09 04:09 PM
MPM BioVentures 2014, L.P.10% OwnerApr 08Sale30.5219,304589,0893,655,906Apr 09 04:10 PM
GADICKE ANSBERT10% OwnerApr 08Sale30.5232,304985,8026,004,568Apr 09 04:47 PM
GADICKE ANSBERT10% OwnerApr 07Sale32.559,678315,0486,052,542Apr 09 04:47 PM
MPM BioVentures 2014, L.P.10% OwnerApr 07Sale32.555,783188,2543,700,880Apr 09 04:10 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 07Sale32.555,783188,2543,700,880Apr 09 04:09 PM